Insulet (NASDAQ:PODD) reported strong Q4 CY2025 results, with sales of $783.8 million exceeding analyst expectations by 2% and non-GAAP EPS of $1.55 beating estimates by 6%. The company’s revenue grew 31.2% year-on-year, and it provided Q1 CY2026 revenue guidance largely in line with analyst predictions. Insulet emphasized its robust business model and disciplined execution as key drivers for its continued success in revolutionizing diabetes care.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Insulet (NASDAQ:PODD) Surprises With Q4 CY2025 Sales
Insulet (NASDAQ:PODD) reported strong Q4 CY2025 results, with sales of $783.8 million exceeding analyst expectations by 2% and non-GAAP EPS of $1.55 beating estimates by 6%. The company’s revenue grew 31.2% year-on-year, and it provided Q1 CY2026 revenue guidance largely in line with analyst predictions. Insulet emphasized its robust business model and disciplined execution as key drivers for its continued success in revolutionizing diabetes care.